International Journal of STD & AIDS > Volume 20, Number 8 > Pp. 566-570

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Tabarsi, P Articles by Masjedi, M Search for Related Content PubMed PubMed Citation Social Bookmarking                      What's this?

Original research articles

First-line antituberculosis drug resistance prevalence and its pattern among HIV-infected patients in the national referral tuberculosis centre, Iran

P Tabarsi MD MPH, E Chitsaz MD , A Moradi MD, P Baghaei MD MPH, P Farnia PhD, M Marjani MD MPH, P Irannejad MD, D Mansouri MD MPH and M Masjedi MD MPH

Mycobacteriology Research Center, National Research Institute of Tuberculosis and Lung Disease, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Correspondence to: Dr E Chitsaz, Masih Daneshvari Hospital, Darabad, Niavaran Sq, Tehran 1955841452, Iran Email: ehchitsaz{at}nritld.ac.ir

The objective of this study was to determine the drug resistance prevalence and its pattern among tuberculosis (TB)–HIV patients in Iran. In this retrospective study, all admitted TB/HIV patients presenting to our tertiary centre during 2005–2007 were considered. After confirmation for TB–HIV, first-line DST was performed for culture-positive patients. The drug resistance patterns and the treatment outcomes were analysed. Of the total 92 TB/HIV patients, 27 were culture negative, and DST were available in 65. Intravenous drug abuse was seen in 59 (90.8%). Thirty-seven (57%) were ‘sensitive’ cases and 28 (43%) were ‘any drug resistance’ cases. Twenty-one (32.3%) were mono-drug, three (4.6%) poly-drug and four (6.1%) were multidrug-resistant TB patients. Previous anti-TB medication was significantly associated with any drug resistance (P = 0.041; 95% confidence interval =0.086–0.984); however, having any drug resistance did not affect the treatment outcome (P = 0.56). Streptomycin showed the highest resistance rate (27%) followed by isoniazid (20%), pyrazinamide (9.8%), rifampin (9.2%) and ethambutol (3%). Drug resistance to antitubercular agents in TB–HIV co-infected patients in Iran is high compared with other reports. Drug resistance is higher among those who have had prior anti-TB medication.

Key Words: TB–HIV co-infection • drug resistance • first-line anti-TB

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?